Determination of Carboplatin's Optimal Plasmatic Exposure

Institut Claudius Regaud

Status: Completed

Conditions: Neoplasms

Treatments: Drug: Carboplatin

Study type: Interventional

Funder types: Other

Identifiers

NCT00145028

04 GENE 05

Details and patient eligibility

About

To determine Carboplatin's optimal exposures(optimal AUCs)and parameters they depend on.

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Carcinoma histologically proved and which must be treated by Carboplatin, excepted weekly administered Carboplatin treatments
• Age > 18 years
• Neutrophils > 1500/mm3, blood-platelets > 100000/mm3
• Patient with intravenous administration route for chemotherapy independent of the one used for blood samples ( for Investigators centers achieving pharmacokinetic examination)
• Well-informed written consent, signed by the patient

Exclusion criteria

• Carboplatin treatment's contra-indication
• Patient with clinically detectable cerebral metastasis
• Pregnant or nursing women
• Patient under guardianship or trusteeship
• Patient whose venous status don't permit a peripheral intravenous administration route's placing (for Investigators centers achieving pharmacokinetic examination)